A phase 3 trial shows that adding polatuzumab vedotin to a standard chemo regimen significantly improves survival in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who can't undergo transplant. The Pola-R-GemOx combo reduced the risk of death by 40% and more than doubled complete response rates compared to chemotherapy alone, establishing a new treatment option for this challenging patient population.
For patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who aren't eligible for a stem cell transplant, treatment options have long been limited — but a new phase 3 trial is changing that picture. The POLARGO study found that adding polatuzumab vedotin to the standard rituximab, gemcitabine, and oxaliplatin (R-GemOx) regimen delivered meaningful survival gains, prompting researchers to call R-GemOx alone "increasingly an outdated standard of care."
The trial enrolled 255 patients across 64 sites in 16 countries, randomly assigning them to Pola-R-GemOx or R-GemOx for up to 8 cycles. After a median follow-up of nearly 25 months, the results were striking across every key endpoint.
By the Numbers:
Why it matters: Many DLBCL patients who relapse never make it to CAR T-cell therapy — only about 25–36% receive it in real-world settings. Pola-R-GemOx offers a potent, non-lymphodepleting salvage option that could also serve as a bridge to CAR T, expanding meaningful treatment access for a vulnerable patient group.
